The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations

The optimal immunosuppression protocol to prevent early acute cellular rejection (ACR) after liver transplantation (LT) avoiding prolonged hospitalization and early hospital readmission is undefined.

• Publication year

  2022

• Venue

  Clinical Transplantation

• Publication date

  2022-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ctr.14614PMID 35143096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunosuppression in liver and intestinal transplantation.

  2021cited by this paper
• Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial

  2020influential reference
• Efficacy and Safety of Basiliximab as Initial Immunosuppression in Liver Transplantation: A Single Center Study.

  2020influential reference
• Immunosuppression in liver transplant.

  2020cited by this paper
• Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial

  2019cited by this paper
• Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

  2019influential reference
• Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation

  2018influential reference
• Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial

  2018cited by this paper
• Rating the certainty in evidence in the absence of a single estimate of effect

  2017cited by this paper
• Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation.

  2015influential reference
• Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

  2015influential reference
• De Novo Sirolimus and Reduced‐Dose Tacrolimus Versus Standard‐Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial

  2014cited by this paper
• De novo use of generic tacrolimus in liver transplantation – a single center experience with one‐yr follow‐up

  2014influential reference
• Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

  2014influential reference
• [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength].

  2014cited by this paper
• GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.

  2013cited by this paper
• Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome.

  2013cited by this paper
• Completely steroid‐free immunosuppression in liver transplantation: a randomized study

  2013cited by this paper
• GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength.

  2013cited by this paper
• A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

  2013cited by this paper
• Tacrolimus Trough Levels, Rejection and Renal Impairment in Liver Transplantation: A Systematic Review and Meta‐Analysis

  2012cited by this paper
• Alemtuzumab induction in non‐hepatitis C positive liver transplant recipients

  2011influential reference
• Reduced‐Dose Tacrolimus with Mycophenolate Mofetil vs. Standard‐Dose Tacrolimus in Liver Transplantation: A Randomized Study

  2011influential reference
• GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

  2011cited by this paper
• Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta‐analysis of controlled studies

  2011cited by this paper
• Basiliximab Induction and Delayed Calcineurin Inhibitor Initiation in Liver Transplant Recipients With Renal Insufficiency

  2011influential reference
• Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations

  2010cited by this paper
• Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients

  2010influential reference
• ATG‐Fresenius Treatment and Low‐Dose Tacrolimus: Results of a Randomized Controlled Trial in Liver Transplantation

  2010cited by this paper
• Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data

  2010cited by this paper
• Once‐Daily Prolonged‐Release Tacrolimus (ADVAGRAF) Versus Twice‐Daily Tacrolimus (PROGRAF) in Liver Transplantation

  2010influential reference
• Two yr mycophenolate mofetil plus low‐dose calcineurin inhibitor for renal dysfunction after liver transplant

  2009influential reference
• Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard‐dose or reduced‐dose tacrolimus in liver transplant recipients

  2009influential reference
• Delayed Introduction of Reduced‐Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT' Study

  2009cited by this paper
• Corticosteroid‐free immunosuppression in liver transplantation: a meta‐analysis and meta‐regression of outcomes

  2009cited by this paper
• Patient Outcomes in Two Steroid-Free Regimens Using Tacrolimus Monotherapy After Daclizumab Induction and Tacrolimus With Mycophenolate Mofetil in Liver Transplantation

  2008influential reference
• Preserving renal function in liver transplant recipients with rabbit anti‐thymocyte globulin and delayed initiation of calcineurin inhibitors

  2008influential reference
• Steroid avoidance in liver transplantation: Meta‐analysis and meta‐regression of randomized trials

  2008cited by this paper
• Tacrolimus Monotherapy in Liver Transplantation: One-Year Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Study

  2008cited by this paper
• Short‐term versus long‐term induction therapy with antithymocyte globulin in orthotopic liver transplantation

  2007influential reference
• Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double‐Blinded Placebo‐Controlled Trial

  2007cited by this paper
• Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis

  2006cited by this paper
• Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

  2005influential reference
• Steroid withdrawal at day 14 after liver transplantation: A double‐blind, placebo‐controlled study

  2004cited by this paper
• Immunoprophylaxis with basiliximab, a chimeric anti–interleukin‐2 receptor monoclonal antibody, in combination with azathioprine‐containing triple therapy in liver transplant recipients

  2002influential reference
• Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial.

  2002influential reference
• Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double‐blind randomized placebo‐controlled trial

  2002influential reference
• Orthotopic liver transplantation using low‐dose tacrolimus and sirolimus

  2001influential reference
• A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

  2001influential reference
• Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.

  2000cited by this paper

• Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive management.

  2026cites this paper
• Hydrogen Sulfide in Experimental Organ Transplantation: From Bench to Bedside.

  2025cites this paper
• Chronic kidney disease at one year after liver transplantation: Role of changes in immunosuppression over three decades

  2025cites this paper
• Basiliximab Induction and Postoperative Steroid-free Immunosuppression With Tacrolimus in Pediatric Liver Transplantation: A Randomized Clinical Trial

  2024cites this paper
• Evaluation of benefits and risks of immunosuppressive drugs in biomaterial-based neural progenitor cell transplantation for spinal cord injury repair

  2024cites this paper
• Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity-score matched intention-to-treat registry study.

  2024cites this paper
• EASL Clinical Practice Guidelines on liver transplantation.

  2024cites this paper
• Consensus document from the Spanish Society for Liver Transplantation: Enhanced recovery after liver transplantation.

  2024cites this paper
• Documento de consenso de la Sociedad Española de Trasplante Hepático. Recuperación intensificada en trasplante hepático

  2024cites this paper
• Consensus document from the Spanish Society for Liver Transplantation: enhanced recovery after liver transplantation.

  2024cites this paper
• Rejection in Liver Transplantation Recipients.

  2024cites this paper
• Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference.

  2023cites this paper